Literature DB >> 25645839

Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013.

Rodrigo E Mendes1, Patricia A Hogan2, Jennifer M Streit3, Ronald N Jones3, Robert K Flamm3.   

Abstract

Linezolid showed MIC50s and MIC90s of 1 μg/ml (for both) against Staphylococcus aureus. Two S. aureus strains exhibited higher MICs (4 to 8 μg/ml) caused by cfr and/or target site mutations, including the first detection of cfr in Poland. Linezolid (MIC50 and MIC90, 0.5 and 1 μg/ml) had potent MICs against coagulase-negative staphylococci (CoNS). Four CoNS had MICs of 16 to 128 μg/ml due to alterations in 23S rRNA and/or L3/L4. Linezolid inhibited all enterococci and streptococci at ≤2 μg/ml, except for one Enterococcus faecium strain (MIC, 8 μg/ml; G2576T [Escherichia coli numbering] mutation).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25645839      PMCID： PMC4356783          DOI： 10.1128/AAC.04784-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Antimicrobial resistance to linezolid.

Authors:  Venkata G Meka; Howard S Gold
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

Review 2.  Current and prospective treatments for multidrug-resistant gram-positive infections.

Authors:  Jeffrey M Rybak; Katie E Barber; Michael J Rybak
Journal:  Expert Opin Pharmacother       Date:  2013-07-22       Impact factor: 3.889

3.  Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Davida S Smyth; Bo Shopsin; David J Farrell; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; David J Farrell; Teresa Spanu; Giovanni Fadda; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2010-09-14       Impact factor: 5.790

6.  Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.

Authors:  Rodrigo E Mendes; Robert K Flamm; Patricia A Hogan; James E Ross; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

7.  Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12).

Authors:  Rodrigo E Mendes; Patricia A Hogan; Jennifer M Streit; Ronald N Jones; Robert K Flamm
Journal:  J Antimicrob Chemother       Date:  2014-01-26       Impact factor: 5.790

8.  ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.

Authors:  Robert K Flamm; David J Farrell; Rodrigo E Mendes; James E Ross; Helio S Sader; Ronald N Jones
Journal:  J Chemother       Date:  2012-12       Impact factor: 1.714

Review 9.  Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Ronald N Jones
Journal:  Drug Resist Updat       Date:  2014-04-06       Impact factor: 18.500

10.  Quantifying type-specific reproduction numbers for nosocomial pathogens: evidence for heightened transmission of an Asian sequence type 239 MRSA clone.

Authors:  Ben S Cooper; Theodore Kypraios; Rahul Batra; Duncan Wyncoll; Olga Tosas; Jonathan D Edgeworth
Journal:  PLoS Comput Biol       Date:  2012-04-12       Impact factor: 4.475
View more
  6 in total

1.  Early Bayesian Dose Adjustment of Vancomycin Continuous Infusion in Children: a Randomized Controlled Trial.

Authors:  Romain Berthaud; Sihem Benaboud; Déborah Hirt; Mathieu Genuini; Mehdi Oualha; Martin Castelle; Coralie Briand; Solène Artru; Lorenzo Norsa; Olivia Boyer; Frantz Foissac; Naïm Bouazza; Jean-Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

2.  A high incidence and coexistence of multiresistance genes cfr and optrA among linezolid-resistant enterococci isolated from a teaching hospital in Wenzhou, China.

Authors:  Yizhi Zhang; Guofeng Dong; Jiahui Li; Lijiang Chen; Haiyang Liu; Wenzi Bi; Hong Lu; Tieli Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-16       Impact factor: 3.267

3.  Detection of a New cfr-Like Gene, cfr(B), in Enterococcus faecium Isolates Recovered from Human Specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program.

Authors:  Lalitagauri M Deshpande; Deborah S Ashcraft; Heather P Kahn; George Pankey; Ronald N Jones; David J Farrell; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

4.  Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results.

Authors:  Rodrigo E Mendes; David J Farrell; Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

5.  Inhibition of chloroplast translation as a new target for herbicides.

Authors:  Kirill V Sukhoverkov; Karen J Breese; Aleksandra W Debowski; Monika W Murcha; Keith A Stubbs; Joshua S Mylne
Journal:  RSC Chem Biol       Date:  2021-11-10

Review 6.  Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China.

Authors:  Beth Lesher; Xin Gao; Yixi Chen; Zhengyin Liu
Journal:  Clinicoecon Outcomes Res       Date:  2016-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.